Filing Details
- Accession Number:
- 0000875320-23-000062
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-19 16:15:42
- Reporting Period:
- 2023-12-15
- Accepted Time:
- 2023-12-19 16:15:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1735944 | Reshma Kewalramani | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-12-15 | 3,058 | $155.57 | 111,769 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-12-15 | 14,077 | $187.53 | 125,846 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-12-15 | 17,135 | $407.00 | 108,711 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-12-15 | 3,058 | $0.00 | 3,058 | $155.57 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-12-15 | 14,077 | $0.00 | 14,077 | $187.53 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2028-02-05 | No | 4 | M | Direct | |
| 1,565 | 2029-02-05 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023.
- Fully vested.
Billionaire Hedge Funds
